title: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue.
abstract: OBJECTIVE
  To determine the effect of eradicating Helicobacter pylori infection on the course of low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
  
  
  METHODS
  Prospective cohort study.
  
  
  METHODS
  University internal medicine clinics, a referral oncology center in southern Switzerland, and a gastroenterology referral center in northern Italy.
  
  
  METHODS
  26 patients with localized primary low-grade gastric MALT lymphoma.
  
  
  METHODS
  Treatment for H. pylori infection (bismuth or omeprazole or both, amoxicillin, and metronidazole for 14 days).
  
  
  METHODS
  Endoscopic biopsy specimens of the gastric mucosa were obtained every 3 to 6 months after treatment for H. pylori infection.
  
  
  RESULTS
  Helicobacter pylori was completely eradicated in 25 of 26 patients, but 4 patients needed second-line antibiotic treatment to eradicate the microorganism. Disappearance or almost total regression of the lymphomatous tissue was observed in 15 of the 25 evaluable patients (60%; CI, 39% to 79%); however, disappearance or almost total regression was evident in the first biopsy specimen after treatment for H. pylori infection in only 8 of the 15 patients.
  
  
  CONCLUSIONS
  Our study confirms recent anecdotal reports of regression of gastric MALT lymphoma after eradication of H. pylori and indicates that the growth of these extranodal lymphomas may depend on H. pylori.
authors.affiliation: Servizio Oncologico, Ospedale San Giovanni, Bellinzona, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: Roggero
authors.forename: E
authors.initials: E
authors.lastname: Zucca
authors.forename: G
authors.initials: G
authors.lastname: Pinotti
authors.forename: A
authors.initials: A
authors.lastname: Pascarella
authors.forename: C
authors.initials: C
authors.lastname: Capella
authors.forename: A
authors.initials: A
authors.lastname: Savio
authors.forename: E
authors.initials: E
authors.lastname: Pedrinis
authors.forename: A
authors.initials: A
authors.lastname: Paterlini
authors.forename: A
authors.initials: A
authors.lastname: Venco
authors.forename: F
authors.initials: F
authors.lastname: Cavalli
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents